• Product Launches & Reception: Zepp launched nine new products in 2025, and expects a similar number in 2026. We believe launches in late Q4-2025, and Q1 2026, including the Amazfit Active Max, Amazfit Active 3 Premium, and Amazfit T-Rex Ultra 2, should support robust revenue growth in H1-2026. Initial reviews highlight strong value relative to their price points, with bright displays, long battery life, and robust fitness tracking, though the products are slightly less polished/advanced than some premium competitors.
  • Supply Chain Advantage: The global AI boom has created a shortage of high-density memory chips, but Zepp is less exposed than many competitors. Since its users prioritize health tracking, and battery life over memory-intensive apps, the company has lower reliance on expensive components, while competitors face rising hardware costs.
  • Financial Position & Outlook: At the end of Q3, working capital and investments net of long-term debt totaled $167M (~$12/share). Management guided Q1-2026 revenue to $50–55M, representing ~35% YoY growth. With recent product launches, and strong guidance, we now expect EPS to turn positive in 2026 (previously 2027), ending a five-year streak of losses.
  • FX Risk: The Middle East conflict has heightened risk-off sentiment, strengthening the US$, and creating near-term FX headwinds. While Zepp’s direct exposure is limited, we believe a stronger US$ may dilute reported international revenue. Higher energy costs may add cost pressure across the supply chain, although we view both effects as temporary.
  • Valuation & Market Context: While the NASDAQ-100 Technology Sector is up 3% YTD, ZEPP is down 50%, a drop we view as disproportionate to its fundamentals. ZEPP trades at 0.45x forward revenue vs. the sector average of 3.27x, an 86% discount.

Price and Volume (1-year)

  YTD 12M
ZEPP -50% 449%
NYSE 3% 24%

* Zepp Health has paid FRC a fee for research coverage and distribution of reports. See last page for other important disclosures, rating, and risk definitions. All figures in US$ unless otherwise specified.

Zepp ranks seventh in global smartwatch sales, behind Apple (NASDAQ: AAPL), Samsung (KOSE: 005930), Garmin (NYSE: GRMN), Fitbit/Google (NASDAQ: GOOGL), Xiaomi (SEHK: 1810), and Huawei. For perspective, Apple ships ~35M units annually; Zepp ships ~3M

Self-branded product shipments jumped 30% in 2025, beating our forecast by 3%, while global smartwatch shipments grew only 4% YoY

Unit Sales & Other Key Metrics

  • In line with industry standards, Zepp retains 70% of the retail price of its products as revenue, while retailers and distributors keep the remaining 30%.

Zepp does not disclose segmented results: 

  • Smart wristbands, and watches, constitute 90%+ of revenue.
  • Self-Branded Products -  Europe & the Middle East account for 50% of sales, followed by North America ( 15-20 %), China (10%), and the rest of the world (15-30 %)
  • Xiaomi  Products – Starting Q1-2025, the company ceased manufacturing products for Xiaomi. Xiaomi owns 20% of Zepp’s outstanding shares

Source: FRC / Company

Revenue rose 41% YoY to $259M, exactly in line with our estimate, driven by stronger unit sales, and a 16% YoY increase in selling prices

Gross margins remained steady YoY, beating our estimate by 0.6โ€ฏpp, and beating the industry average for wearable tech (36%), and consumer electronics (25%)
We believe new higher-priced product launches should support margin growth in 2026

Source: Company, FRC

Zepp spent 21% of revenue on sales/marketing, while most majors typically spend 5-10%; a key reason unit sales grew faster than the sector
EPS rose YoY from ($0.29) to ($0.16) on higher revenue, but missed our ($0.11) estimate, due to several one-time operating costs

Operating expenses rose 9% YoY, 8% above our estimate, primarily due to one-time items including costs related to IP protection, prepaid marketing expenses, and investments in sales and distribution infrastructure. Excluding these, expenses would have been broadly in line with our estimate, and roughly flat YoY.

Source: Company, FRC

Working capital, and investments, net of long-term debt was $167M, or $12/share

FRC Projections and Valuation 

Per consensus forecasts, global smartwatch shipments, which fell 7% in 2024, rebounded 4% in 2025 and are expected to grow 7 –10% in 2026, driven by product upgrades, rising health awareness, AI integration, and broader wearables adoption.

Market Share and Growth

Source: FRC / Various

Zepp products accounted for 1.9% of global smartwatch shipments in 2025, up from 1.5% in 2024

Given the recent product launches and upbeat guidance for Q1, we are raising our revenue and EPS forecasts
We now forecast EPS to turn positive this year, ending a five-year streak of losses, instead of in 2027

Source: FRC

As a result, our DCF valuation increased from $47 to $50/share

Source: FRC/S&P Capital IQ

Sector EV/forward revenue is down 24% since our previous report in November 2025
ZEPP remains undervalued, trading at just 0.45x forward revenue (previously 1.71x), well below the sector average of 3.27x (previously 4.31x)
Applying 3.27x to our 2026 revenue forecast for Zepp, we arrived at a comparables valuation of $62/share (previously $82/share)

We reiterate our BUY rating, and adjust our fair value estimate from $ 64.37 to $56.28/share, based on the average of our DCF and comparables valuations. The valuation decline reflects lower sector valuations, partially offset by our higher DCF valuation. Zepp delivered strong 2025 performance, with unit shipment growth significantly outpacing the broader smartwatch market, supported by new product launches, and increased marketing spend. Although EPS missed our estimate due to one-off costs, underlying fundamentals continue to strengthen, with rising market share and a clearer path to profitability in 2026.

Risks We believe the company is exposed to the following key risks (not exhaustive):

  • Competition and innovation
  • Supply chain
  • Reliance on third-party manufacturers
  • Tariffs
  • Operates in a marketing intensive industry
  • FOREX

We are maintaining our risk rating of 3 (Average)

APPENDIX